No way....this stock is crash and burn..

ustrading what happen VTPI bottom fall out...I lost big today...

USTrader what the happen the bottom dropped. I should sell..Bought in at .034 200000 shares

DNAG has over 1 billion outstanding shares.....DNAG may have idea, programs and a few patents but the biggie is they have NO CASH and they are in debt.. There would have to be a REVERSAL of 1000/1 or more, which is not good. There may be a few and the word is few that will make money in a spike in price but for the vast investor to buy now your just throwing money away. But the big question will DNAG or DNAP or CLYC which is the same company DNAPrint over the last 12 years, will they receive monies to go foward. This company has had nine lifes. The country banks are felling and they are to gett money from where. Please don't say the US government. This company is not really a company. A company make money for the share holders. The mass shareholder (750 million share) is own by the company personnel. DP owns 250 million share. Be very careful you may lose all you money.
Not everyone can make money on these outstanding shares.
If it walks like a duck and quack like a duck and looks like a duck its a _ _ _ _. The point is no what you have.
Do your DD.

The estimate comes from the federal government's ongoing National Health and Nutrition Examination Survey, which provides the clearest snapshot of the American population's health through dozens of measurements, lab tests and survey questions.

The new findings, published in the Journal of the American Medical Association, are likely to further encourage use of a vaccine against HPV approved in June by the Food and Drug Administration for girls and women ages 9 to 26.

Its maker, Merck & Co., until recently was lobbying state legislatures to mandate vaccination of middle school girls - a step that more than 18 states, including Florida, are moving toward.

There are dozens of strains of HPV, but only some can lead to cancer. Two - HPV-16 and HPV-18 - are responsible for about 70 percent of cervical cancers. The vaccine protects against both, plus two strains that cause genital warts.

Enough is enough. DNAPrint price is falling. Stockholder101 and jever000 are buying stock that will not make money on a long term bases...Penny traders look for spikes with volume buying--simply.... There is a HUGE amount of debt with a HUGE amount of outstanding share. DNAPrint is a penny stock for a reason. They have 1 billion shares to do with as they seen fit...LONG term shareholders are the only ones that get smashed in penny stocks. If you haven't sold on the spike you may have to wait years for the next spike... GOOD LUCK

BUYINS.NET: CSCA, DNAG Have Also Been Removed From Naked Short List Today

Feb 22, 2007 (M2 PRESSWIRE via COMTEX) -- BUYINS.NET, www.buyins.net, announced today that these select companies have been removed from the NASDAQ, AMEX and NYSE naked short threshold list: Chardan South China Acquisition Corporation (OTCBB: CSCA), DNAPrint Genomics, Inc. (OTCBB: DNAG). For a complete list of companies on the naked short list please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to www.buyins.net.
Chardan South China Acquisition Corporation (OTCBB: CSCA) is a blank check company whose IPO went effective in August 2005. Its mission statement was to acquire an operating business based south of the Yangtze River in the People's Republic of China ("PRC"). In January, 2007 CSCA announced that it had entered into an Agreement in Principal to merge with Head Dragon Holdings, Limited, a Hong Kong Holding company that owns 100% of Liaoning GaoKe Energy Group ("GaoKe"), the largest private Chinese engineering company providing design, construction, installation, and operating expertise for distributed power generation and micro power grids in the PRC. Although GaoKe's principal offices are located north of the Yangtze River in the PRC, CSCA's board and management will obtain shareholder approval for the change in geography in the normal course of closing the transaction. With 7 million shares outstanding and 16 shares declared short as of January 2007, there is no longer a failure to deliver in shares of CSCA.

DNAPrint Genomics, Inc. (OTCBB: DNAG) operates as a developer of genomics-based products and services primarily in biomedical and forensics markets in the United States. Its primary product is PT-401, a Super EPO' (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients. The company's other products under development include PT-501, PT-502, and PT-503 theranostics products for the treatment of attention deficit hyperactivity disorder, drug abuse, and depression, respectively. DNAPrint Genomics' is also developing diagnostic products, including OVANOME for ovarian cancer, STATINOME for the safety of statins, and DIABETES-CD59 for diabetic complications. In addition, it offers DNAWitness product suite, which enables medical examiner's offices, special task forces, sheriffs' departments, and other forensics experts in the law enforcement field to determine genetic heritage from DNA samples obtained from crime scenes; and ANCESTRYbyDNA and EURO-DNA, both are genealogy products that determine genetic heritage. Further, the company provides sequencing and genotyping services to industrial customers. DNAPrint Genomics has strategic alliances with Moffitt Cancer Center, Beth Israel Deaconess Medical Center, and NeoCodex, Inc.; and a collaborative research agreement with Beth Israel. It also has a license agreement with Harvard Medical School, and a research sponsorship agreement with Massachusetts College of Pharmacy and Health Sciences. The company, formerly known as Lexington Energy, Inc., was founded by Tony Frudakis. DNAPrint Genomics was incorporated in 1983 and is headquartered in Sarasota, Florida. With 417 million shares outstanding and 100,102 shares declared short as of January 2007, there is no longer a failure to deliver in shares of DNAG.

About BUYINS.NET

WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.

BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.net/squeezetrigger.pdf. The SqueezeTrigger database of nearly 1,200,000,000 short sale transactions goes back to January 1, 2005, and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005, because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month's short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.

All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.

BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk.

BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.

CONTACT: Thomas Ronk, CEO, www.buyins.net Tel: +1 800 715 9999 e-mail: Tom@buyins.net

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.




(C)1994-2007 M2 COMMUNICATIONS LTD

-0-


Search for Dun & Bradstreet reports on this company.

jever000, A person should never buy a stock just because they likes it, or because they happen to have the money available at the time. Hesitating too long in deciding to sell on this kind of a move may leave you holding too long.

I'm get tired of the pumpers giving bad opinions what they think is going to make this stock work. The truth is they don't know what DNAPrint is up against...The only true fact you can truth is the price chart.Go back to a ten year price chart it will show you where DNAPrint is...DNAPrint ticker was DNAP before the last reverse split. They change it to DNAG. Before you first time buyer buy, be aware that for 7 years DNAPrint as said alot of stuff and were are still at a penny... Now DNAPrint has had 2 spikes in price but it was all manipulation by the Market Makers and has always come right back down to where we are...MM's control the price...WHY?, DNAPrint doesn't make money.. not yet..

jever000 why did you buy today it going lower.. it the truth

stockholder101--has told you it was going up.. BUT it going down, WHY it has no volume--simply there is half billion share to play with. DNAPrint and la jolla got to eat so they use the investor money. Its the only money they have....sorry stockholder101 but you have got to stop leading first time investors on...stockholder will take your money...

DNAPRINT GENOMICS INC
Price: 0.0145 -0.0005 -3.33%
Bid: 0.0145[-]
Ask: 0.015
Open: 0.0155
Volume: 1,269,532

It will go lower tomorrow---you want to bet. You don't make sense jever000. you want to buy at .014 buy tomorrow or do you want to buy at .013 wait a few days... your trying to buy with no volume you will lose if you try to buy at .015

Chaz2344, For one to be an idiot in this game is not to make money were you can...most people would only throw pennies in to a wishing well but for one to throw thousands of dollars in to a wishing well that just stupid. Stockholder is giving you bad advise to buy DNAG at this time....the volume has disappeared.

Jever000, you must not be placing the order or your place under the bid price. MM's would take your money if they could see it. With low volume they would take your money in a heart beat if you were with in the bid and ask. And that is where it stayed all day..you are pumping again and again....

International ... Tony Frudakis (US) - Forensics DNA Print Genomics ...
www.hum-molgen.org/meetings/meetings/3156.html

Mutation Detection 2007, Xiamen, China
23 - 27 September, 2007

IXth International Symposium on Mutations in the Genome
This meeting aims to bring together all those interested in Mutation Detection methods and their application in Biology, Medicine and Agriculture. It is a forum where developers of methodology can exchange ideas, and those responsible for diagnostics can compare results with specific methods. Those in agriculture, microbiology and non-medical fields are encouraged to attend. It is also a source of new commercilization opportunites and partnerships. These meetings are now recognized and attended by the specialists in Mutation Detection and are continuing to be the only such grouping of scientists anywhere else in the world. We hope you can attend.

The Mutation Detection Symposium this year will be held Xiamen which is located on the South East Chinese coast. These symposia have a tradition of a wonderful cultural program that compliments the scientific program allowing all participants to freely interact and exchange ideas in magnificent surroundings with plenty of time for communication between the invited inventors and major users and committed audience who have experience in mutation detection. There is a strictly limited number of 200 registrants on a 1st come 1st served basis to allow maximum interaction between delegates, so if you would like to secure a place please register now. Abstracts can only be submitted by those who are registered for the meeting.

Reports of previous meetings may be seen in the following publications:


Santorini 2005: "Technophiles seek genomic imperfections with the Greek gods at Atlantis", Scott H.F., Nature Genetics Vol. 37, No. 10 p 1019 - 1021.
Palm Cove 2003: A meeting report and selected papers from the last meeting in Palm Cove, Australia, July 2003: Human Mutation: Vol. 23, No. 5 (2004)
Bled 2001: A meeting report and selected papers from the meeting in Bled, Slovenia, April 2001: Human Mutation: Vol. 19, No. 4 (2002)


Organized by: Genomic Disorders Research Centre
Invited Speakers: Michael Bergeron (CAN) - DNA Sequencing
Richard Cotton (AUS) - Variation Databases
Ron Davis (US)* - Molecular Inversion Probes
Johan den Dunnen (NETH) - Pathogenic or Not? & Software
Evan Eichler (US) - Copy Number Variation
Xavier Estivill (ESP) - Application
Tony Frudakis (US) - Forensics DNA Print Genomics
Ivo Gut (FRA) - Mass Spec Application
Wei Huang (CHINA)* - Application
Li Jin (CHINA) - Application
Pui-Yan Kwok (US) - Complex Disorders & Molecular Methods
Qingge Li (CHINA) - TBA
Zuhong Lu (CHINA)* -Nanotechnology
Yusuke Nakamura (JAP) - High Throughput Genotyping
Mats Nilsson (SWE) - DNA Analysis
Tomi Pastinen (CAN) - Allelic Imbalance in Gene Expression
Stephan Schuster (US) - 454 Application
Ann-Christine Syvänen (SWE) - TBA
Nongjian Tao (US) - DNA Conductivity
Jeff Tza-Huei Wang (US) -Quantum Dot Sensors
Jun Yu (CHINA) - TBA
Jin Billy Li (US) - New Technology for Resequencing
(* = not yet confirmed)


Deadline for Abstracts: 15 June 2007

Registration: Registration Fees
Registration includes administration costs, conference materials, all coffee breaks, all lunches, all dinners including the Welcome Reception and Gala dinner as well as an excursion. Details of all these events may be seen on the Social Program page of the meeting website.

Category "Earlybird"
Upto 15/06/07 Standard
16/06/07 - 17/09/07 Late & Onsite
From 18/09/07
Standard AU$ 788 AU$ 898 N/A
Student AU$ 688 AU$ 788 N/A

What is there to lie about.. Call the Company investor relations... I kept on getting an answer machine so I dailed for the operator at DNAPrint. I told the operator that I couldn't get through to investor relations and that I would like to talk to someone about the companies price and the moffit /merck deal...a woman came on I started toask questions. She said nothing more has happen since the last shareholder meeting ....And that she could only comment on public announcements... I told you that it was tuff to get something out of her so I was poking around..But I asked her if she was buy DNAPrint stock and she said no. She said that she was invested in her last job ..stockholder101 there is nothing to lie about..You forget you are not the only one that has a steak in DNAPrint. I am not doing what you are doing. I'm not guessing. Now settle down if you are right about Moffit/merck great. But what I was told I have stated....

lizm67, she also said that she couldn't say anymore because it was illegal to do so... you are right..

They also told me that the reason they left the old office was that the building was to be knocked to put in condos. The new office is also cheaper rent than the old office.... She said that they have more room and the lab is set up...

If an employee knew DNAPrint stock was going up wouldn't you buy??? The one I talked to said No I am not buying DNAPrint stock.... Now you say it going to explode on the 22 of Feb..

stockholder101 and if the Moffit/merck deal doesn't mature then what....They are running out of money to do research that is what they told me yesterday...Do you ever call DNAPrint and get news from them... I ask about la jolla and if their share were to run out in return she said we have 1 billion share to distribute .. And she left it at that.... I ask her about the price and any news in the short term. She came back and said DNAPrint is a long term investment. I told her that it been 7 years how much longer. She say long term is diffinitely the way is going. I asked her if she was buying DNAG she said no. She had other investments from her last job.

I don't take the word of people on this board I go to the horses mouth, DNAPrint is the horse. If you don't beleive what I tell you call the company....

I got one question why would you keep on buying knowing that DNAPrint has 1 billion shares to do with anyway they want. There is no possible way you can get rich by being a long term investor......you are mental ....now short term maybe you have a chance......did anyone call the company today.. I did,I asked them about the price roll. They said that DNAPrint is a long term investment.But they have said this for 6 years. She said that DNAPrint needs money for research and right now they are running short in funding. I also asked if there was any chance in a reversal, she said that there was no talk of a reversal at this time..But DNAPrint has a long way to go in making money.. I asked about the Merck and Moffit deal if Dnaprint had anything to do with it. She said NO nothing to her knowledge. Said said all I can say is DNAPrint is in the same situation since the last shaereholder meeting...I had to poke with questions with really no up lifting hope for the near future. I asked her if she was buying the stock. SHE said NO...Invest relation sucks at DNAPrint or its just DNAPrint has nothing going on at his time..

If DNAPrint do better than that ia PR we are in trouble....going down to 1 cent....

This NEWs will send DNAG price over 5 cent next week... The question is simple... YOU do or don't you believe in DNAPrint.. If you want to make money next week buy and sell for the short term, this is a no brainer. Long term is alot harder to see where DNAPrint is going. But I believe DNAPrint will break through the sub penny catagory...GOOD LUCK TO ALL..lets make some money...

DNAPrint tiny run today was because of the mammoth article....posted 29 Jan 2007...down tomrrow

http://www.genengnews.com/news/bnitem.aspx?name=11953339

DNAPrint Genomics Continues to Support Police in Mammoth Lakes Murder Case
Jan 29 2007, 4:00 AM EST
MARKETWIRE

Jan 29, 2007 SARASOTA, FA MARKET WIRE

DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced its continuing assistance to the Mammoth Lakes Police Department as Dr. Hector Gomez, DNAPrint Chairman and Chief Medical Officer, joined in a special outreach to the Spanish-speaking community in further attempts to find the killer of a woman whose ethnicity was definitively established by the Company's proprietary DNAWitness(TM) product.

Dr. Gomez was featured in a segment of the Univision network program "Aqui Y Ahora" on Thursday, January 18, as he documented the Company's role in the Mammoth Lakes murder case and explained how the ethnicity of the dead woman was identified using DNAPrint's product.

"I was pleased to take part in this outreach to the Spanish-speaking community as a demonstration of DNAPrint's ongoing commitment to the Mammoth Lakes Police Department and to law enforcement agencies in general," Dr. Gomez said. "DNAPrint's support does not end with the taking of samples and the delivery of a report. The Company will assist law enforcement agencies in any way possible to identify suspects and bring them to justice, and this includes reaching out to the media."

DNAPrint's role has been crucial from the beginning, according to Sgt. Paul Dostie of the Mammoth Lakes Police Department. "(DNAPrint's involvement) completely turned our investigation around and opened up a new world to us regarding DNA, in that none of the information DNAPrint provided us is available in any government-run crime lab," Sgt. Dostie said.

Police records in Mammoth Lakes, Calif., note that the remains of a woman were found outside the town in May 2003 and that a preliminary investigation showed that she had been murdered. The corpse was initially identified as the remains of a southeast Asian woman, but Mammoth Lakes police reports show that they used DNAPrint's DNAWitness(TM) 2.5 test to confirm the identification, and that the test contradicted the original finding. Instead, the test showed that the murder victim was 100% Native American.

"When I called the Mammoth Lakes PD to discuss the results, I'll never forget the response from Sgt. Dostie," said Dr. Matt Thomas, DNAPrint's Senior Scientist and Lab Manager. "He asked if I was really sure about the result, because the forensic anthropologist identified her as probably Asian. I assured him that our test results were accurate, and suggested other independent testing that could corroborate our findings. In addition, DNAPrint performed a number of blind samples from Native American and Hispanic groups that Sgt. Dostie collected, all of which were properly identified."

The Mammoth Lakes PD sent hair, bone and mtDNA samples from this case to other experts. The work on these samples has further refined the story in this case and has corroborated DNAPrint's initial results.

"There is solid evidence that DNAPrint's identification kits, when teamed with the Company's extensive ancestry database, are second to none in forensic accuracy," stated DNAPrint President and Chief Executive Officer Richard J. Gabriel. "Investigative agencies from all over the globe, including the FBI with cases in California and Louisiana, and New Scotland Yard in the case of the Minstead Rapist, have relied on our products and our technical support as they attempt to crack difficult cases. DNAPrint stands ready to assist Sgt. Dostie and his colleagues worldwide in solving these heinous crimes."

The Native American woman's description and a police artist's reconstruction of her face were immediately distributed to the media. Mammoth Lakes authorities also contacted the Univision television network. Dr. Gomez, whose native language is Spanish, also responded to a call for assistance in explaining the technology.

"One goal of the investigation was to bring media exposure to the case, specifically Spanish language media," Dr. Thomas said. "A testament to Sgt. Dostie's tenacity in this case has been all the independent and innovative testing he has pulled together, which corroborated our original findings and, better yet, has provided him some very good investigative leads."

The investigation continues, Dr. Thomas said.

DNAWitness(TM) employs patent-pending, database-driven methods to infer elements of physical appearance from crime scene DNA and to allow forensic investigators to "paint" molecular portraits of a suspect. This innovative forensic technology has already been used in some 150 cases, including the arrest and conviction of Derrick Todd Lee for a series of murders in Louisiana and in New Scotland Yard's search for the so-called Minstead Rapist, a serial sex offender who is operating in an area south of London.

DNAWitness(TM) determines the percentage of European, East Asian, Native American, and Sub-Saharan African markers in a person's DNA. This ratio for an individual is termed Bio-Geographical Ancestry (BGA), representing general characteristics that can be matched with a searchable database containing information and photographs collected from samples around the world, leading to more accurate determinations of criminal perpetrators.

Retinome(TM) 2.0 can be combined with the DNAWitness(TM) product to determine a person's eye color. The Company's patent-pending technology identifies additional markers covering newly identified and informative regions of the human pigmentation gene OCA2. The Company has also developed a Retinome 2.0 capillary electrophoresis kit, which permits investigators to test Retinome 2.0 in their own laboratories, obviating the need to ship their samples to DNAPrint (though that option is still available).

DNAPrint also is able to perform tests for mitochondrial and Y DNA trace samples or mixtures. DNAPrint and its wholly owned subsidiary Trace Genetics have the largest volunteer Native American databases of DNA.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.


Company Contact:
Richard Gabriel
CEO and President
941-366-3400
-or-
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848

SOURCE: DNAPrint Genomics, Inc.

GOMEZ has said nothing about a Merck contract..Shareholder101 has dreamed this all up. "in his opinion"

Bag8gerl,, you don't want the new investors and the old to lose sight of what is true and want is a dream....Shareholder101 and others are playing with DNAGster hard earn money to fill their pocket with dreams. And they will dump leaving the one that beleive in a simply dream....One day DNAPrint may make a profit...They haven't yet..that day will be reality

DNAPrint is NO were involved in this statement contract for FORIDA...also this is old NEWS it has been worked in to the price...charts say down we go....But maybe DNAPrint will get 2 or 3 million of the 15 million. It is a well know fact that DNAPrint is working with Moffit.State OKs Merck Deal for Moffit--yahooooooo!

Merck has 750 employees and DNAPrint has 12 employees.....why would any one leave Merck. Dr. Gomez looks to me has gone down hill....A company with money and a company with no money. What up with that... I sure they would remember why he left..

Why in the world would Dr. Gomez leave Merck......DNAPrint is a long ways from the top.

People here on this board beleive in the work that DNAPrint has shown and wants to do....But if there is NO PRs so far this year is because there is nothing to say.none ,zippo, nil,natta.

Stockholder101--Come on man, All your post have been work in to the market price. Its OLD NEWS. This one is what the company has been promising for 7 years, http://www.wwsb.com/frameset.asp?page=http://www.wwsb.com/news/health_stories.asp?39
This is old news. We all beleive DNAPrint has what it takes but the market insiders will not allow DNaprint in. Simple because they don't need them yet. Dnaprint lives on the shareholder investment to stay alive. It is the only way for them to stay a float...But one day if Tony Frudakis does lose his vision may become a money making company.Crash and burn can hurt anyone self esteem.
DNAPrint has been around for 7 years. We have had 2 spikes in price but the price tumble right back to 1 cent. We had an reversal and right back to 1 cent.DNAPrint live on the shareholder.. but they have no choice. But we the shareholder do have a choice..The market insiders are DNAPrint biggest hurdle. If they would let DNAPrint in the sky is the limit...but don't hold you breath....

Stockholder101--Frudacky has a mean point. But I can maybe answer that DNAPrint only has 12 employees and they will need the help of the University and clout to reassure Merck sharholders that there money is not being thrown away.

Frudaky,, Please understand that I truely beleive DNAPrint has what they say they do. And they could do great things with the technology but the market insiders don't want it. If Tony Frudakis had the monies to introduce and maintain a service that the larger companies need we would be sworing. Right now insiders would lose money to DNAPrint. They aren't going to let DNAprint in..The more TV and high profile cases that use DNAPrint name may keep them going. How long do you think Tony Frudakis will crash and burn. I like the technology but I don't like the way DNAPrint has used shareholder to stay afloat. But on the other hand Frudakis wanted the doors to stay open. He had no choice but to use the sharholders, in a reversal. Now it one day at a time for the shareholders. Day trading is the only way you can make money in DNAG right now and feel good about a trade. LONG term very risky for me I don't feel it the right move for me. GO DNAPRINT

what? how many shares were you trying to buy. 50,000 or less you should have been filled.

Chaz2344 I would say you are in some what of a close call to what will happen. Between 1 cent and 2 cent is alot of shares to lose in the penny world... and if it goes below 1 cent? But then if it goes to to 10 cents or more?....look at the chart for the past 7 years how many spikes------- 2 (TWO) and both time it come tumbling down. But DNAPrint could be one in 1 million companies that will rocket to success. Rome wasn't build a day. GOOD LUCK

GCBR you may want to talk to shareholder he may help you make some money.